#abs0948 #acr22 @rheumnow perception on fertility&ART in pts w/rheum Dx: 60% believe their Dx affects fertility/25% believe meds do: most cited MTX, steroids, TNFi, HCQ, NSAIDs. 92% heard of ART but unsure if safe or successful w/their Dx. Hx of infertility 29%/only 52% go w/ART https://t.co/lmaM773gP5

There are good reasons why you might want to treat pre-RA. Hard to walk past this promise #ACR22 @RheumNow https://t.co/YHmIl5dsID

Did you know? Teratogens may take the form of: ✳️Drugs & chemicals ✳️Physical agents ✳️Infections ✳️Metabolic conditions #ACR22 @Rheumnow #MedTwitter https://t.co/GfHL28RYjm

USA vs Canada It's kicking off and a super hot topic The Great Debate: To Treat or Not? The Role of DMARDS in Subclinical Rheumatoid Arthritis Holers/Deane (treat 🇺🇸) El Gabalawy/Pope (don't treat 🇨🇦) What more do you want, #ACR22? Bring it on @RheumNow https://t.co/DroQdnSQHf

Terrier @TerrierBen et al Mepolizumab in vasculitic type EGPA in MIRRA. Vasculitic features similar in patients who did/did not achieve remission. Decreased flares of all type, including vasculitic. @RheumNow #ACR22 Abstr#1075 https://t.co/0MkJvnCnf1 https://t.co/ZxbDqlvgae

Favorable kidney outcomes observed for BEL vs PBO in pts with SLE, including fewer kidney flares, greater kidney improvement (SELENA-SLEDAI), less kidney worsening (BILAG), and improved eGFR. Abs 0352 #ACR22 @RheumNow https://t.co/w50uEYVDup https://t.co/JyKZEZG6DZ

Bekker et al. Safety of avacopan across 3 trials. Rates of AEs, SAEs, infection all lower in avacopan group. @RheumNow #ACR22 Abstr#1077 https://t.co/n4zhC2zf8k https://t.co/Q8raSEERah

#ACR22 Abstr# Interesting data for IMID patients who had #COVID. A cohort study in Norway (1/3 had RA and mostly on TNFi; 6% RTX) showed greater anti-Spike Ab in 4th vaccine vs 3rd dose. However, the greatest was in those with 3 x doses + COVID infection (Hybrid) @RheumNow https://t.co/hGFSGqJtBT

Benavides-Villanueva et al. Single centre 28 case series of IVIG in AAV. Used due to relapse in 25, concomitant infection in 3. BVAS 0 in 56.5% at month 24, glucocorticoid sparing effect. @RheumNow #ACR22 Abstr#1079 https://t.co/wfg1HSKM9O https://t.co/DuReVU2jA4

Abs 0714 at #ACR22 real-world obs study finds seropositive and seronegative RA patients had similar clinical effectiveness 1 year after starting bDMARD or JAKi. @RheumNow https://t.co/UrVgZ0zVno https://t.co/LnXMfOkQIp

Early TNFi use and cardiovascular events in AS Abstract #0415 #ACR22 @RheumNow 📍17.6k patients, 91% male, 80% white 📍TNFi initiators were younger with lower prev. of HTN and DM 📍TNFi was associated with higher risk of incident CVD, CVA, and MACE https://t.co/7bCkfk7EYY

I questioned HCQ dose reducing in my recent newsletter & podcast; more evidence! Receiving less HCQ = more damage and more CVD Observational, not clearly causal, but should make you wonder... Are we sure we should be shooting for <5mg/kg/day? #ACR22 @RheumNow #0982 https://t.co/SuAwSumgu1